These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3085928)

  • 1. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.
    Melamed E; Bitton V; Zelig O
    Clin Neuropharmacol; 1986; 9(2):182-8. PubMed ID: 3085928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
    Melamed E; Bitton V; Zelig O
    Neurology; 1986 Jan; 36(1):100-3. PubMed ID: 3941762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of supplemental carbidopa on bioavailability of L-dopa.
    Cedarbaum JM; Kutt H; Dhar AK; Watkins S; McDowell FH
    Clin Neuropharmacol; 1986; 9(2):153-9. PubMed ID: 3085927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
    Chen H; Fang J; Li F; Gao L; Feng T
    Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease.
    Mostile G; Nicoletti A; Dibilio V; Luca A; Raciti L; Sciacca G; Cicero CE; Vasta R; Donzuso G; Contrafatto D; Zappia M
    Clin Neuropharmacol; 2017; 40(1):6-10. PubMed ID: 27879548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of clinical response and plasma dopa levels in Parkinson's disease.
    Tolosa ES; Martin WE; Cohen HP; Jacobson RL
    Neurology; 1975 Feb; 25(2):177-83. PubMed ID: 1167646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
    Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M
    Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
    Algeri S; Ruggieri S; Miranda F; Casacchia M; Morselli PL; Agnoli A
    Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F; Chaná P
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake.
    Andersson I; Granerus AK; Jagenburg R; Svanborg A
    Acta Med Scand; 1975 Nov; 198(5):415-20. PubMed ID: 1199816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diurnal responsiveness to apomorphine.
    Gancher ST; Nutt JG
    Neurology; 1987 Jul; 37(7):1250-3. PubMed ID: 3601094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
    Petelin LS; Vartanian KZ; Romenskaia LKh
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(12):1810-3. PubMed ID: 602554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
    Shoulson I; Glaubiger GA; Chase TN
    Neurology; 1975 Dec; 25(12):1144-8. PubMed ID: 812004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.
    Dietrichson P; Presthus J; Holmsen R
    Eur Neurol; 1975; 13(4):339-49. PubMed ID: 1149754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.